Briles, D.Hollingshead, S.Paton, J.Ades, E.Novak, L.van Ginkel, F.Benjamin Jr, W.2006-06-192006-06-192003Journal of Infectious Diseases, 2003; 188(3):339-3480022-18991537-6613http://hdl.handle.net/2440/3051Intranasal infection of mice with certain strains of capsular group 19 Streptococcus pneumoniae can result in focal pneumonia in the absence of bacteremia. Using this model of murine pneumonia, we demonstrated that immunization with recombinant forms of either pneumococcal surface protein A (PspA) or PdB (a genetically detoxified derivative of pneumolysin) elicited significant protection against focal pulmonary infection. This may be the first demonstration that a proposed vaccine antigen can protect against pneumococcal pneumonia. The best protection was obtained by immunizing mice with a mixture of PspA and PdB, indicating that the protection elicited by these antigens can complement each other. This result is in agreement with previous studies that used pneumococcal sepsis and nasal colonization models and demonstrate that the best protein vaccines for prevention of infection may be those that include more than one protection-eliciting pneumococcal protein.en© 2003 by the Infectious Diseases Society of America. All rights reserved.LungAnimalsMice, Inbred CBAMiceStreptococcus pneumoniaePneumonia, PneumococcalFocal InfectionDisease Models, AnimalBacterial ProteinsRecombinant ProteinsVaccines, SyntheticStreptolysinsPneumococcal VaccinesVaccines, CombinedAntigens, BacterialImmunizationAdministration, IntranasalFemaleJournal article002003008710.1086/3765710001843169000012-s2.0-004266548359091Paton, J. [0000-0001-9807-5278]